Kairos Pharma, LTD.

LOS ANGELES, CA · CIK 0001962011 · Biotech · Public

Novel cancer therapies targeting drug resistance and immune response restoration

kairospharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$4.2M
2 Form D · Jan 2025
20 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$675,000
Private capital raisedForm D · SEC$3,497,500
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2090General Translation, Inc.—$2.4M
2091CNS Pharmaceuticals, Inc.—$23M
2092CAYMAN CHEMICAL COMPANY, INCORPORATED——
2093Kairos Pharma, LTD.—$4.2M
2094MONON BIOVENTURES, LLC——
2095Sequor Pharamaceuticals LLC——
2096MIRNA ANALYTICS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Hyun BaeDirector
  • Neil BhowmickExecutive Officer
  • Hansoo Michael KeyoungDirector
  • Ramachandran MuraliExecutive Officer
  • Doug SamuelsonExecutive Officer
  • Rahul SinghviDirector
  • John YuDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.